Literature DB >> 19805935

The use of magnesium sulphate for the treatment of severe pre-eclampsia and eclampsia.

Jamilu Tukur1.   

Abstract

BACKGROUND: Pre-eclampsia and eclampsia are important causes of maternal and perinatal morbidity and mortality in the developing countries. There is need to provide the most effective management to pre-eclamptic and eclamptic patients. There is now evidence that magnesium sulphate is the most effective anticonvulsant.
METHOD: In this article , a literature review was made on the contribution of pre-eclampsia and eclampsia to maternal mortality and how it can be curtailed by the use of magnesium sulphate.
RESULTS: The drug is administered by the Pritchard or Zuspan regimen, although modifications in the two protocols have been reported.
CONCLUSION: A Nigerian national protocol has been developed on its use. There is need for further training of health workers on how to use this important drug.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19805935     DOI: 10.4103/1596-3519.56232

Source DB:  PubMed          Journal:  Ann Afr Med        ISSN: 0975-5764


  13 in total

1.  Case of ascites in pre-eclampsia.

Authors:  Sushil Chawla; P Kumar; M Bhalla
Journal:  Med J Armed Forces India       Date:  2012-06-15

2.  The Feto-Maternal Outcome of Preeclampsia with Severe Features and Eclampsia in Abakaliki, South-East Nigeria.

Authors:  Leonard Ogbonna Ajah; Nelson Chukwudi Ozonu; Paul Olisaemeka Ezeonu; Lucky Osaheni Lawani; Johnson Akuma Obuna; Emeka Ogah Onwe
Journal:  J Clin Diagn Res       Date:  2016-09-01

Review 3.  Magnesium in obstetric anesthesia and intensive care.

Authors:  Marija S Kutlesic; Ranko M Kutlesic; Tatjana Mostic-Ilic
Journal:  J Anesth       Date:  2016-11-01       Impact factor: 2.078

4.  Rupture of bicornuate uterus.

Authors:  Sheela Jayaprakash; Lakshmidevi Muralidhar; G Sampathkumar; Rajivkumar Sexsena
Journal:  BMJ Case Rep       Date:  2011-10-28

5.  Maternal and fetal outcomes after introduction of magnesium sulphate for treatment of preeclampsia and eclampsia in selected secondary facilities: a low-cost intervention.

Authors:  Jamilu Tukur; Babatunde Ahonsi; Salisu Mohammed Ishaku; Idowu Araoyinbo; Ekechi Okereke; Ayodeji Oginni Babatunde
Journal:  Matern Child Health J       Date:  2013-09

6.  Factors influencing the use of magnesium sulphate in pre-eclampsia/eclampsia management in health facilities in Northern Nigeria: a mixed methods study.

Authors:  Olugbenga Oguntunde; Zulfiya Charyeva; Molly Cannon; William Sambisa; Nosakhare Orobaton; Ibrahim A Kabo; Kamil Shoretire; Saba'atu E Danladi; Nurudeen Lawal; Habib Sadauki
Journal:  BMC Pregnancy Childbirth       Date:  2015-06-03       Impact factor: 3.007

7.  Evaluation of a low-cost, low-power syringe pump to deliver magnesium sulfate intravenously to pre-eclamptic women in a Malawian referral hospital.

Authors:  Erica Skerrett; Edward Kommwa; Kelley Maynard; Alexa Juarez; Ronald Mataya; Rebecca Richards-Kortum; Z Maria Oden
Journal:  BMC Pregnancy Childbirth       Date:  2017-06-19       Impact factor: 3.007

8.  Magnocaine: Physical Compatibility and Chemical Stability of Magnesium Sulphate and Lidocaine Hydrochloride in Prefilled Syringes.

Authors:  Sara Houlihan; Diane Decarie; Cindy Benes; Richard Cleve; Marianne Vidler; Laura A Magee; Mary H H Ensom; Peter von Dadelszen
Journal:  J Obstet Gynaecol Can       Date:  2016-06-29

Review 9.  An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management.

Authors:  Jeffrey Michael Smith; Richard F Lowe; Judith Fullerton; Sheena M Currie; Laura Harris; Erica Felker-Kantor
Journal:  BMC Pregnancy Childbirth       Date:  2013-02-05       Impact factor: 3.007

Review 10.  No Hypertensive Disorder of Pregnancy; No Preeclampsia-eclampsia; No Gestational Hypertension; No Hellp Syndrome. Vascular Disorder of Pregnancy Speaks for All.

Authors:  Yifru Berhan
Journal:  Ethiop J Health Sci       Date:  2016-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.